# Semaglutide Cardiovascular Outcomes: What the Research Shows **By TelosRX Editorial Team** · 2026-08-26 **Semaglutide cardiovascular outcomes now have landmark trial backing: the SELECT study showed a 20% reduction in major cardiac events in people with obesity and pre-existing heart disease — an effect that appears partly independent of weight loss. Eligibility is [subject to evaluation at TelosRX](https://telosrx.com), where approval requires review by a licensed provider.** ## Why Cardiovascular Outcomes Matter for GLP-1 Users Most people start semaglutide for weight loss. The cardiovascular data that followed was a genuine surprise: heart benefits extended well beyond what the scale predicted. GLP-1 receptors aren't only in the gut. They sit on heart muscle cells, blood vessel walls, and the macrophages central to atherosclerotic plaque. That anatomical distribution gives the drug a reach that weight reduction alone doesn't explain. The research now spans multiple large trials, a 2024 FDA approval specifically for cardiovascular risk, and emerging data on kidney outcomes. Here's what the evidence shows. ## The SELECT Trial: Core Data SELECT is the definitive cardiovascular outcomes trial for semaglutide in a non-diabetic population. Researchers enrolled 17,604 adults — all with overweight or obesity, all with pre-existing cardiovascular disease, and critically, none with type 2 diabetes. Half received semaglutide 2.4 mg weekly; half received placebo. Median follow-up: approximately 34 months. The primary endpoint was major adverse cardiovascular events (MACE): cardiovascular death, nonfatal heart attack, or nonfatal stroke. Outcome Semaglutide Group Placebo Group Relative Risk Reduction MACE composite 6.5% 8.0% 20% (HR 0.80, p<0.001) Nonfatal myocardial infarction Lower Reference 26% reduction Nonfatal stroke Lower Reference 12% reduction Cardiovascular death Lower Reference 7% reduction Body weight at 104 weeks −9.39% −0.88% — Source: [NEJM SELECT Analysis](https://www.nejm.org/doi/full/10.1056/NEJMc2400414) and [SELECT trial review, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11439431/). The hazard ratio of 0.80 means for every 100 cardiac events in the placebo arm, the semaglutide arm saw roughly 80. That gap held across subgroups — men, women, varying baseline BMI, different CV risk profiles. The consistency of this signal across subgroups is one of the more compelling aspects of the dataset, because cardiovascular outcome trials often see benefit concentrated in specific populations. ## A Mechanism Beyond Weight Loss This is where the research gets most clinically interesting. Prespecified analyses found semaglutide's cardiovascular benefit was only weakly correlated with waist circumference reduction. Patients who lost little weight still showed directionally similar cardiac benefits to those who lost more. Researchers identified several probable mechanisms running in parallel with weight loss: - **Anti-inflammatory signaling:** GLP-1 receptors on macrophages appear to dampen the chronic inflammation that drives atherosclerotic plaque formation and rupture. - **Direct myocardial effects:** Preclinical models show GLP-1 reduces ischemia-reperfusion injury — cell death following a blocked-then-restored blood supply, the mechanism of most heart attacks. - **Blood pressure reduction:** A modest but consistent systolic BP reduction appears with semaglutide, partly independent of weight. - **Lipid profile improvement:** Reductions in LDL cholesterol and triglycerides accompany treatment, both established cardiac risk markers. For context on how GLP-1 receptor agonists work mechanically, see our overview: [How Does GLP-1 Work? Mechanism & Weight Loss Explained](https://www.telosrx.com/blogs/glp1/how-does-glp1-work-mechanism-weight-loss). ## Heart Failure: A Specific Subgroup Signal A prespecified SELECT subgroup analysis looked at participants with established heart failure across both preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF). The findings were consistent with the overall trial. Semaglutide reduced both MACE and composite heart failure endpoints in participants with and without clinical heart failure, regardless of heart failure subtype. A separate trial, STEP-HFpEF, added to this signal: patients with obesity-related HFpEF on semaglutide showed significant improvements in six-minute walk distance, symptom burden scores, and body weight versus placebo. HFpEF has historically been difficult to treat. The semaglutide data is among the most meaningful signals in that space in years. ## The Oral Semaglutide Signal: SOUL Trial The SOUL trial — the first dedicated cardiovascular outcomes trial for oral semaglutide — reported its primary results in 2025. The oral formulation reduced cardiovascular events by 14% over four years in patients with type 2 diabetes and high cardiovascular risk. This matters because it shows the cardiovascular benefit isn't route-of-administration dependent. Injectable and oral semaglutide produce directionally consistent cardiac signals, though different dosing and pharmacokinetics mean the two formulations aren't interchangeable in clinical use. See how compounded injectable semaglutide is evaluated in a telehealth context: [Compounded Semaglutide via Telehealth: A 2026 Patient Guide](https://www.telosrx.com/blogs/glp1/compounded-semaglutide-telehealth-2026). **Considering whether GLP-1 therapy fits your situation?** [TelosRX](https://telosrx.com) provides asynchronous, online-first evaluation — no scheduled appointment needed. All decisions are subject to review and approval by a licensed provider. ## Renal Outcomes: The FLOW Trial Kidney disease and cardiovascular disease track together: about 50% of people with chronic kidney disease die from cardiac causes before their kidneys fail. So the kidney data for semaglutide is directly relevant here. The FLOW trial — a dedicated renal outcomes study — found semaglutide reduced major adverse kidney events by 24%, including slowing disease progression and reducing cardiovascular or kidney-related death. Source: [PubMed — FLOW trial results, oral semaglutide study](https://pubmed.ncbi.nlm.nih.gov/40162642/). The consistency across cardiac, metabolic, and renal outcomes strengthens the case for GLP-1's systemic effects beyond its weight-loss mechanism. ## What the Evidence Means in Practice In March 2024, the FDA approved semaglutide (brand name Wegovy) specifically to reduce cardiovascular mortality risk — the first weight-loss medication to earn a dedicated cardiovascular mortality indication. That's a regulatory milestone. The practical takeaway for patients with obesity and established CVD: starting semaglutide for weight loss likely adds a cardiovascular risk-reduction effect running in parallel. These aren't separate decisions; they're layered benefits from one medication. Important limits in the evidence: SELECT enrolled people with pre-existing cardiovascular disease. The data doesn't directly translate to people without established CVD, where the cardiac evidence is less mature. Compounded semaglutide is not FDA-approved; it's prepared under federal compounding regulations, and access is subject to provider-issued prescription following evaluation of individual clinical factors. Also worth noting: the SELECT trial population was 72% male and 87.5% Caucasian. How the cardiovascular benefits extend across different demographic groups — women, non-White populations, and varying baseline cardiac risk profiles — is an active area of ongoing research. Subgroup analyses in the trial suggest directional consistency, but clinicians watch these gaps. The renal data adds another layer of clinical relevance. For patients managing both obesity and chronic kidney disease — a common pairing — semaglutide's simultaneous cardiac and kidney signals make the case for treatment stronger than either signal alone. This convergence of metabolic, cardiac, and renal outcomes is what distinguishes this drug class from prior-generation weight-loss agents. Where does compounded semaglutide fit? It's not FDA-approved — brand-name Wegovy carries the indication. But the compounded form shares the same active molecule, and access through asynchronous telehealth platforms like TelosRX follows the same clinical logic: provider evaluation, individual clinical factors, ongoing monitoring. What differs is the access pathway, not the underlying pharmacology. For a related consideration — maintaining lean muscle mass while on GLP-1 therapy — see: [Muscle Loss on Semaglutide: Preserving Lean Mass on GLP-1](https://www.telosrx.com/blogs/glp1/muscle-loss-on-semaglutide-lean-mass-glp1). And if you're comparing approaches: [Microdosing Semaglutide: Benefits, Risks, and Who It's For](https://www.telosrx.com/blogs/glp1/microdosing-semaglutide-benefits-risks-guide). ## Frequently Asked Questions ### Does semaglutide improve cardiovascular outcomes? Yes — specifically in adults with obesity or overweight and pre-existing cardiovascular disease. The SELECT trial demonstrated a 20% relative reduction in major adverse cardiovascular events over approximately three years. The FDA approved semaglutide for this indication in March 2024. Access and eligibility are subject to medical approval by a licensed provider. ### What did the SELECT trial show about semaglutide and the heart? SELECT enrolled 17,604 non-diabetic adults with obesity and established CVD. Semaglutide 2.4 mg weekly reduced the composite of cardiovascular death, nonfatal MI, or nonfatal stroke by 20% versus placebo (HR 0.80, p<0.001). Nonfatal heart attacks drove the largest share of benefit at a 26% reduction. ### Is the cardiovascular benefit from semaglutide just from losing weight? Partially — but not entirely. Prespecified analyses showed the benefit was present across weight-loss categories and weakly correlated with waist circumference changes. Researchers believe additional mechanisms — anti-inflammatory signaling on vascular and cardiac tissue, blood pressure reduction, and direct GLP-1 receptor effects on myocardial cells — contribute independently of adiposity change. ### How long before semaglutide cardiovascular benefits appear? Benefit curves in SELECT began separating within the first few months of treatment. However, the most definitive risk reduction data comes from the full 34-month median follow-up. Cardiovascular risk reduction is a long-game endpoint — it's not a short-term signal like weight loss. ### Can semaglutide help non-diabetic patients lower heart disease risk? Yes — SELECT was specifically designed in non-diabetic adults. The cardiovascular evidence applies directly to people with obesity and established CVD who don't have type 2 diabetes. Individual eligibility remains subject to evaluation by a licensed provider based on clinical factors. ### Is semaglutide FDA-approved for cardiovascular disease? Yes. In March 2024, the FDA approved Wegovy (semaglutide 2.4 mg) to reduce cardiovascular death, nonfatal heart attack, and nonfatal stroke in adults with obesity or overweight and established CVD. Compounded semaglutide is not FDA-approved and is prepared under federal compounding regulations; access requires a provider-issued prescription. ### Does tirzepatide also show cardiovascular benefits? Emerging data looks favorable. A 2025 real-world study in _Nature Medicine_ found both semaglutide and tirzepatide reduced cardiovascular outcomes in type 2 diabetes. The SURMOUNT-MMO trial is evaluating tirzepatide specifically for cardiovascular outcomes in obesity without diabetes — full results are maturing. See our comparison: [Tirzepatide vs Semaglutide: Compounded GLP-1 Options Explained](https://www.telosrx.com/blogs/glp1/tirzepatide-vs-semaglutide-compounded-glp1-comparison). _TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._ Start your private evaluation at [TelosRX](https://telosrx.com). **Tags:** cardiovascular outcomes, GLP-1, heart disease, research-evidence, SELECT trial, semaglutide, weight loss --- > Source: [Telos RX](https://www.telosrx.com/blogs/glp1/semaglutide-cardiovascular-outcomes-research)